Stopsack KH, et al. - Researchers examined the link between low expression of PLZF (promyelocytic leukemia zinc finger, a tumor suppressor gene) and clinical outcomes in patients diagnosed with primary prostate cancer. They carried out a prospective follow-up of the Health Professionals Follow-up Study (HPFS; n = 254) and the Physicians’ Health Study (PHS; n = 150), as well as in The Cancer Genome Atlas (n = 333), to evaluate PLZF mRNA expression in the patients. PTEN status (using copy numbers and IHC), as well as transcriptional activation of the MAPK pathway, was assessed. Follow-up was performed in patients from HPFS and PHS, to determine metastases and prostate cancer–specific mortality (median, 15.3 years; 113 lethal events). Independent of clinicopathologic features, Gleason score, and androgen receptor (AR) signaling, the chances of developing lethal prostate cancer were more among patients in the lowest quartile of PLZF expression vs those in the highest quartile. In primary prostate cancer, a worse prognosis was reported in relation to low expression of the tumor suppressor gene PLZF.